Gout News and Research

Latest Gout News and Research

Dietary components do not have impact on RMD outcomes

In 2022, EULAR - the European Alliance of Rheumatology Associations - published new recommendations regarding lifestyle behaviors and work participation to prevent progression of rheumatic and musculoskeletal diseases (RMDs).

1 Nov 2022

Study reveals immune characteristics of long-COVID

Researchers perform antibody profiling against SARS-CoV-2, several endemic pathogens, as well as vaccine antigens among rheumatic disease patients.

2 Oct 2022

What is the risk of SARS-CoV-2 infection among gout patients?

The main outcome of a new study study was to assess the risk of SARS-CoV-2 infection among gout patients.

12 Sep 2022

Gout medicine fails to improve cardiovascular outcomes in patients with ischemic heart disease

The gout medicine allopurinol has failed to reduce the primary endpoint of nonfatal myocardial infarction, nonfatal stroke or cardiovascular death in patients with ischaemic heart disease, according to late breaking research presented in a Hot Line session today at ESC Congress 2022.

28 Aug 2022

Researchers unravel a novel molecular target of eicosapentaenoic acid

Eicosapentaenoic acid (EPA) is an essential nutrient belonging to the omega-3 group of polyunsaturated fatty acids (PUFAs). As the human body cannot synthesize PUFAs, dietary supplements containing EPA are required for normal physiological functions. Found abundantly in natural sources like fish, hemp oil, and linseed oil, EPA is known to exhibit anti-inflammatory, neuroprotective, and cardiovascular protective activities.

9 Aug 2022

Gout flares associated with subsequent cardiovascular events

Experts at the University of Nottingham, in collaboration with experts at Keele University, have found that the risk of heart attacks and strokes temporarily increases in the four months after a gout flare.

2 Aug 2022

Low doses of a less commonly used drug may be a better treatment option for gout

Gout occurs when urate crystals accumulate in the joints, and xanthine oxidase inhibitors such as febuxostat are a mainstay of therapy to help reduce blood urate levels in affected patients.

7 Jul 2022

Novel genetic mapping study traces links between DNA variations and blood proteins

A new genetic mapping study led by researchers at the Johns Hopkins Bloomberg School of Public Health traces links between DNA variations and thousands of blood proteins in two large and distinct populations. The results should help researchers better understand the molecular causes of diseases and identify proteins that could be targeted to treat these diseases.

3 May 2022

Probenecid shows activity against respiratory syncytial virus

A new study describes the antiviral activity of the approved drug probenecid against respiratory syncytial virus.

29 Apr 2022

Using customized 'mini-antibodies' to mitigate chronic inflammation

Researchers at the Universities of Bonn and Sao Paulo have succeeded in mitigating chronic inflammation in mice using customized "mini-antibodies."

19 Apr 2022

Exploring biomedical literature and clinical trial records to identify new drug combinations for COVID-19 treatment

Researchers extensively searched publicly available SARS-CoV-2 biomedical literature to identify drug combinations that could effectively treat COVID-19.

7 Mar 2022

EULAR develops new recommendations for cardiovascular risk management

EULAR, the European Alliance of Associations for Rheumatology, has developed new recommendations for CVR management in people with gout, vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD), Sjögren's syndrome (SS), systemic lupus erythematosus (SLE), and antiphospholipid syndrome (APS).

23 Feb 2022

Colchicine holds promise to reduce the risk of severe COVID-19

A recent article, published in Rheumatology and Therapy, reviews the potent evidence of colchicine against the SARS-CoV-2 infection.

7 Feb 2022

Scientists elucidate the structure of central cellular inflammatory switch

Researchers at the Universities of Bonn and Regensburg have elucidated the structure of a central cellular inflammatory switch.

4 Feb 2022

MD Anderson and Yingli Pharma announce strategic alliance to advance many oncology programs

The University of Texas MD Anderson Cancer Center and Yingli Pharma US, Inc. today announced a strategic alliance to advance several oncology programs from preclinical discovery through clinical development.

20 Jan 2022

Anti-inflammatory drug used to treat gout does not reduce the risk of COVID-19 mortality

Colchicine, a cheap anti-inflammatory drug normally used to treat gout, doesn't lessen COVID-19 severity or stave off the risk of death from the infection in hospital patients, finds a pooled analysis of the available evidence, published in the open access journal RMD Open.

23 Nov 2021

Is gout a risk factor for COVID-19?

A team of international scientists has recently determined the association between gout and risk of coronavirus disease 2019 (COVID-19) related death in a large cohort of patients. Their findings reveal that gout can significantly increase the risk of COVID-19 and related mortality, with women having a higher risk than men. The study is currently available on the medRxiv* preprint server.

4 Oct 2021

Limited evidence colchicine reduces COVID-19 related hospitalization

The present randomized clinical trial attempted to study if colchicine will effectively hasten recovery and reduce COVID-19 associated hospitalizations or death.

27 Sep 2021

UGA research offers hope for a viable therapeutic to combat COVID-19

As COVID-19 cases continue to skyrocket across the U.S. and the world, few options are available for treating patients infected with the SARS-CoV-2.

11 Sep 2021

Researchers explore the fate of dietary fructose in the body

In today's fast-paced world, the dependence on the widely available "fast" foods and beverages has risen. These foods are typically low in fiber and essential nutrients, and often consist of high amounts of added sugar. This shift in dietary trends, accompanied by a sedentary lifestyle, has been attributed to the rise in various metabolic disorders like diabetes, fatty liver disease, and heart disease.

31 Aug 2021